Novo Nordisk reported positive topline results from its STEP Young Phase 3 trial. The study evaluated once-weekly semaglutide in children aged 6 to 12 living with obesity.
The trial met its primary endpoint by achieving a superior reduction in Body Mass Index (BMI) at 68 weeks compared to placebo. Both study groups received lifestyle modifications alongside treatment.
Approximately 40.4% of children treated with semaglutide were no longer classified as having obesity. In contrast, 0% of the placebo group reached this milestone.
The safety profile remained consistent with previous trials. Researchers identified no new concerns regarding growth or pubertal development.
Detailed results will be presented at ObesityWeek 2026 in Washington, DC, from November 14–17, 2026. Novo Nordisk also issued a routine update regarding its ongoing share repurchase program.